Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hologic's Debt-to-EBITDA or its related term are showing as below:
FRA:HO1'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.1 Med: 2.25 Max: 15.98
Current: 2.35
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hologic was 15.98. The lowest was 1.10. And the median was 2.25.
FRA:HO1's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.585
vs FRA:HO1: 2.35
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hologic Debt-to-EBITDA Related Terms
Hologic Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Hologic's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:HO1 vs WST, COO, ALGN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Hologic's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hologic Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hologic's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hologic's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.
Hologic (FRA:HO1) has a Debt-to-EBITDA of 1.93 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hologic. This is 14% below median its historical median of 2.25. Over the past decade, Hologic's Debt-to-EBITDA has ranged from 1.10 to 15.98.
Is Hologic's Debt-to-EBITDA too high?
Hologic's current Debt-to-EBITDA of 1.93 is 14% below median its 10-year median of 2.25. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 15.98. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. Hologic's value of 1.93 is 21.8% above this industry median. Overall, Hologic has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Hologic's Debt-to-EBITDA compare to WST and COO?
Hologic's Debt-to-EBITDA of 1.93 can be compared against companies in the Medical Devices & Instruments industry. The industry median Debt-to-EBITDA is 1.59. Hologic's value of 1.93 is 21.8% above this benchmark. Historically, Hologic's own Debt-to-EBITDA has ranged from 1.10 to 15.98 over the past decade. While the company's 10-year median is 2.25 vs. the industry median of 1.59, Hologic has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hologic's current Debt-to-EBITDA of 1.93 is 21.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hologic. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hologic's current Debt-to-EBITDA is 1.93, which is 14% below median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hologic stock overvalued right now?
Hologic (FRA:HO1) has a current Debt-to-EBITDA of 1.93. The stock's GF Value™ is €70.17, compared to a current price of €65.00 — trading 7.4% below its estimated fair value. The current Debt-to-EBITDA is 1.93, which is 14% below median its 10-year median of 2.25 and 21.8% above the Medical Devices & Instruments industry median of 1.59. Hologic's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hologic (FRA:HO1), the current Debt-to-EBITDA is 1.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hologic (FRA:HO1) Overvalued in 2026?
Based on GuruFocus' analysis, Hologic stock appears to be undervalued.
The current stock price of €65.00 is trading 7.4% below its estimated GF Value™ of €70.17.
Key valuation signals for FRA:HO1:
Debt-to-EBITDA: 1.93 (14% below median its 10-year median of 2.25)
GF Value™: €70.17 vs. price of €65.00 (7.4% below fair value)
Industry Position: 21.8% above the Medical Devices & Instruments median
No single metric tells the full story. See the FRA:HO1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
57GF Score
Get the complete analysis for FRA:HO1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HO1 has been successfully added to your 
